Evidence map›Paper›PMID 42699527›Full record

ArticleCancer pathogenesis and therapy2026

Integrin α3

Weijie Ma, Hongyuan Zhao, Reggie R Fan, Chihong Zhou, Dingning Liu, Shuai Chen, Tianhong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weijie MaDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.
Hongyuan ZhaoDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.
Reggie R FanDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.
Chihong ZhouDepartment of Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, 95817, USA.
Dingning LiuDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, 95616, USA.
Shuai ChenDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, 95616, USA.
Tianhong LiDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Integrin α3 (ITGA3), which heterodimerizes with integrin β1, has emerged as a potential biomarker and therapeutic target in several epithelial malignancies; however, its clinical relevance in breast cancer remains incompletely characterized. This study evaluated Methods: Immunohistochemistry (IHC) was performed on archival breast cancer specimens using tissue microarrays ( Results: ITGA3 protein expression was detected in 85.2% of breast cancer specimens and was significantly higher in HR-positive/HER2-negative and HER2-positive tumors compared with TNBC ( Conclusion: Elevated

Indexed as

BiomarkersBreast cancerIntegrin alpha3Neoplasm recurrencePrognosis

Identifiers

PMID42699527
PMCPMC13543809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.